MetaCap

Hemab Therapeutics Statistics

NASDAQ: COAGHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

39.29-0.57 (-1.43%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Hemab Therapeutics by the numbers

Hemab Therapeutics has a market capitalization of $1.84 billion based on 46.73M shares outstanding. With trailing EPS of $-3.55, Hemab Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 7.0% above its 50-day average and 5.4% above its 200-day average.

Average daily trading volume is 495.96K shares, or about $19.5 million in dollar volume.

Summary generated from market data by MetaCap's automated system. Methodology

COAG valuation vs. peer median

COAG compared with the median of 8 peer companies
MetricCOAGPeer medianDifference
Market cap$1.84B$1.72B+7%
Avg. volume495.96K2.25M-78%

Peer median across 8 companies: BCRX, REPL, LYCA, MAZE, VIR, BEAM, RXRX, ALVO.

Valuation

Price and trading

Previous close
39.86
Open
39.50
Day range
38.77 – 40.19
52-week range
23.00 – 55.42
Beta
—
Volume
347.01K

Dividends and events

Annual dividend
None
Next earnings date
Nov 10, 2026

Additional statistics

Market Cap
1.84B
Forward Pe
-14.82
Eps
-3.55
Dividend Yield
0.00%
Dividend Rate
0.00
Week52 High
55.42
Week52 Low
23.00
Avg Volume
495.96K
Shares Outstanding
46.73M
Ma50
36.72
Ma200
37.27
Earnings Date
Nov 10, 2026
Pct From52w High
-29.11%
Pct From52w Low
70.83%

Related